Last updated: September 4, 2026
Methoxy polyethylene glycol-epoetin beta, marketed primarily as Mircera, is a long-acting erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease. Its commercial position rests on reduced dosing frequency, established nephrology use, and long-term supply relationships with dialysis providers. Its growth has been constrained by lower hemoglobin treatment targets, safety concerns affecting the ESA class, U.S. dialysis reimbursement changes, competition from epoetin and darbepoetin, and emerging hypoxia-inducible factor prolyl hydroxylase inhibitors.
Roche developed Mircera. CSL Vifor has held U.S. commercialization rights, while Roche has retained commercial activities in other markets through its pharmaceutical organization and regional partners. Mircera has no FDA-approved biosimilar listed in the Purple Book as of the latest publicly available FDA records reviewed for this analysis.[1]
What is methoxy polyethylene glycol-epoetin beta?
Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator, commonly abbreviated CERA. It is a recombinant erythropoietin derivative chemically linked to a single polyethylene glycol chain.
The PEG modification extends systemic exposure compared with epoetin alfa, epoetin beta, and darbepoetin alfa. Mircera is administered less frequently than conventional ESAs:
| Product |
Active agent |
Typical dosing pattern in CKD |
Commercial significance |
| Procrit/Epogen |
Epoetin alfa |
Several times weekly or weekly |
Mature, low-cost ESA |
| Eprex |
Epoetin alfa |
Several times weekly or weekly |
Major international competitor |
| Aranesp |
Darbepoetin alfa |
Weekly or every two weeks |
Long-acting ESA competitor |
| Mircera |
Methoxy polyethylene glycol-epoetin beta |
Every two weeks or monthly, depending on treatment stage |
Lowest-frequency established ESA option |
| Jesduvroq |
Daprodustat |
Oral daily treatment |
Non-ESA oral competitor in U.S. dialysis patients |
Mircera is indicated for anemia caused by chronic kidney disease in adult patients on dialysis and adult patients not on dialysis. The U.S. label excludes use as a substitute for red-blood-cell transfusions and carries the ESA class warning for increased risks of death, myocardial infarction, stroke, venous thromboembolism, and tumor progression or recurrence in certain oncology settings.[2]
What is the FDA and international regulatory status of Mircera?
The FDA approved Mircera in November 2007 for anemia associated with chronic kidney disease. The European Commission granted marketing authorization in 2007, giving Roche an early position in the long-acting ESA segment.[3]
U.S. regulatory status
Mircera is licensed under biologics application BLA 125164. The reference product is regulated as a biologic rather than as a conventional small-molecule drug. Consequently, generic manufacturers cannot use the ordinary abbreviated new drug application pathway used for small-molecule products.
A competing manufacturer must generally pursue the biosimilar pathway under Section 351(k) of the Public Health Service Act. A biosimilar application must address analytical similarity, pharmacokinetics, pharmacodynamics, immunogenicity, and, where required, clinical data.[4]
The original 12-year U.S. reference-product exclusivity period ran from Mircera’s first licensure in 2007 and expired in 2019. That expiration removed the statutory reference-product barrier, but it did not eliminate patent, manufacturing, regulatory, or commercial barriers to biosimilar entry.
Orange Book status
Mircera is not an Orange Book-listed small-molecule product. The Orange Book is not the principal FDA database for biologic reference products. Patent and exclusivity information for biologics is addressed through the Purple Book framework and applicable BLA records.[1]
This distinction affects litigation strategy. A biosimilar applicant does not file a conventional Paragraph IV certification against an Orange Book patent listing for Mircera. The relevant process is the biologics patent-dispute framework under the Biologics Price Competition and Innovation Act, often called the “patent dance,” together with separate patent litigation if the reference sponsor asserts patents.
When did Mircera lose exclusivity?
Mircera’s 12-year U.S. biologic exclusivity ended in 2019. The date did not create automatic market entry because biosimilar approval still requires FDA review and any enforceable patent rights may remain relevant.
| Milestone |
Date or period |
Effect |
| European authorization |
2007 |
Established Roche’s international market position |
| U.S. FDA approval |
November 2007 |
Started U.S. reference-product exclusivity |
| U.S. biologic exclusivity |
2007-2019 |
Prevented submission approval of a competing biosimilar for 12 years |
| U.S. exclusivity expiration |
2019 |
Opened the statutory pathway for biosimilar competition |
| U.S. biosimilar status |
No approved Mircera biosimilar identified in FDA Purple Book records reviewed |
Maintains practical market protection |
What patents protect methoxy polyethylene glycol-epoetin beta?
Mircera’s protection has historically involved composition-of-matter claims covering PEGylated erythropoietin derivatives, manufacturing processes, conjugation chemistry, pharmaceutical compositions, and methods of treating anemia.
The patent estate should be analyzed in four layers:
Composition patents
Composition claims can cover the covalent conjugate of erythropoietin and methoxy polyethylene glycol, including molecular architecture, linker chemistry, substitution patterns, and defined molecular-weight distributions.
These claims are potentially the most important barriers because a biosimilar manufacturer must produce a molecule with a similar structure while avoiding infringement of any still-enforceable claims.
Manufacturing and conjugation patents
Manufacturing claims may cover:
- Production of recombinant erythropoietin
- Site-selective or controlled PEGylation
- Purification of the conjugated product
- Control of aggregate levels
- Removal of unconjugated erythropoietin and free PEG
- Formulation and stability processes
Manufacturing patents can remain commercially relevant after reference-product exclusivity expires because biosimilar developers must replicate a complex process without necessarily using the sponsor’s process.
Formulation patents
Potential formulation claims include aqueous injectable compositions, pH ranges, stabilizers, surfactants, container systems, and storage conditions. These claims are usually narrower than core composition patents but can affect the commercial presentation of a biosimilar.
Mircera is supplied as a prefilled syringe and in other injectable presentations depending on jurisdiction. A competing manufacturer may avoid a formulation claim by changing excipients, container configuration, concentration, or presentation.
Method-of-use patents
Method claims may cover treatment of renal anemia, dose conversion from other ESAs, maintenance dosing, and administration schedules. Such claims may be less commercially durable than composition claims because treatment protocols can be designed around them, and some uses may carry limited practical exclusivity after the base product is established.
No single patent expiration date should be treated as the end of Mircera protection. The relevant date depends on the jurisdiction, patent family, patent-term adjustment, terminal disclaimers, claim scope, and whether the asserted claims survive validity and infringement challenges.
How many patents cover Mircera?
The effective estate is a family of patents rather than one controlling patent. Patent counts vary depending on whether the analysis includes continuations, national-stage applications, expired claims, divisionals, and patents assigned to affiliates or licensed entities.
For commercial diligence, the relevant questions are:
- Which claims cover the active conjugate itself?
- Which claims remain unexpired in the target country?
- Which patents are listed or disclosed for the reference product?
- Can a biosimilar process avoid the manufacturing claims?
- Are method-of-use patents relevant to the intended label?
- Has the sponsor granted licenses or settled disputes?
The absence of an Orange Book listing means a simple Orange Book patent-expiry analysis is not sufficient for Mircera.
Which companies are challenging Mircera?
No FDA-approved U.S. biosimilar to Mircera was identified in the FDA Purple Book records reviewed for this analysis.[1] The competitive threat therefore comes mainly from other anemia treatments rather than a launched Mircera biosimilar.
ESA competitors
Epoetin alfa remains the principal low-cost competitor. Darbepoetin alfa competes directly on longer dosing intervals and established dialysis use. In Europe and other markets, epoetin beta and biosimilar epoetins add price pressure.
Oral HIF-PH inhibitors
HIF-PH inhibitors are the most important newer technology class. Daprodustat, marketed in the United States as Jesduvroq, was approved for anemia from CKD in adults who have been receiving dialysis for at least four months.[5] The class stimulates endogenous erythropoietin production and alters iron metabolism through an oral mechanism.
HIF-PH inhibitors can compete with Mircera by reducing injection burden, particularly for patients who are not receiving regular in-center dialysis. Their disadvantages include class-specific safety considerations, treatment restrictions, drug-interaction issues, and the need for longer commercial experience.
What market forces affect Mircera demand?
U.S. dialysis reimbursement
The U.S. ESRD prospective payment system placed injectable anemia drugs inside the dialysis bundled payment structure. Before bundling, dialysis providers had stronger incentives to use separately reimbursed ESA products. After implementation, providers gained a greater incentive to reduce drug acquisition cost and optimize dosing.
This change favored established lower-cost epoetins and increased purchasing scrutiny across the ESA category.[6]
Lower hemoglobin targets
Clinical practice shifted toward more conservative ESA dosing after trials linked aggressive hemoglobin correction with cardiovascular and thrombotic risks. The TREAT trial reported higher risks of stroke and other adverse outcomes with darbepoetin alfa in patients with diabetes, CKD, and anemia who were not receiving dialysis.[7]
Lower target hemoglobin levels reduce ESA volume per patient and weaken the growth outlook for all ESAs, including Mircera.
Dosing convenience
Mircera’s commercial advantage is strongest where monthly administration reduces nursing time, injection frequency, inventory complexity, or missed doses. This advantage is more valuable in settings where labor costs and treatment coordination matter more than the lowest acquisition price.
The advantage is weaker in large dialysis networks with standardized administration protocols and strong purchasing leverage.
Oral competition
HIF-PH inhibitors could shift treatment from injectable ESA products to oral therapy in selected patient populations. The risk is greater in non-dialysis CKD, where patients do not already receive regular injections in a dialysis center.
What is the financial trajectory of methoxy polyethylene glycol-epoetin beta?
Roche does not consistently report Mircera as a standalone global revenue line in its current financial disclosures. Sales are grouped within broader pharmaceutical categories or regional product portfolios. As a result, a precise current global Mircera revenue series cannot be derived from Roche’s consolidated reports alone.[8]
The commercial trajectory has nevertheless followed a recognizable pattern:
| Period |
Financial direction |
Main drivers |
| 2007-2010 |
Launch and expansion |
Novel long-acting profile and European/U.S. adoption |
| 2011-2015 |
Stabilization and pressure |
U.S. dialysis bundling, ESA safety concerns, mature competition |
| 2016-2019 |
Mature-product decline |
Lower dosing intensity, contracting pressure, reference-product aging |
| 2020-2024 |
Late-life portfolio economics |
No identified U.S. biosimilar launch, but pressure from established ESAs and oral alternatives |
| Forward outlook |
Stable-to-declining |
Retention of installed use offset by class substitution and price pressure |
Mircera remains commercially valuable even without high growth. Long-term dialysis contracts, physician familiarity, manufacturing scale, and a limited number of direct biologic competitors can support recurring revenue. The product is more likely to function as a cash-generating mature asset than as a growth driver for Roche or CSL Vifor.
What licensing deals affect Mircera?
Roche partnered with Vifor Pharma for U.S. commercialization of Mircera. The arrangement gave Vifor access to an established long-acting ESA while allowing Roche to use Vifor’s nephrology and dialysis commercial infrastructure in the United States.[9]
The commercial importance of the agreement is greater than a conventional co-promotion arrangement because the U.S. dialysis market is concentrated among large provider networks. Contract access, formulary positioning, supply reliability, and payer negotiations materially affect product utilization.
The parties’ economic arrangements, including transfer pricing, royalties, and current profit allocation, are not fully disclosed in public financial reporting.
What litigation and settlement risks affect Mircera?
Mircera’s litigation risk is primarily biosimilar-related rather than Paragraph IV-related.
A potential biosimilar entrant would face:
- FDA 351(k) regulatory review
- BPCIA information-exchange and patent-dispute procedures
- Composition and manufacturing patent analysis
- Possible injunction or launch-at-risk exposure
- Payer and dialysis-provider contracting requirements
- Switching and substitution questions
No broadly reported U.S. Mircera biosimilar settlement or commercial launch was identified in the FDA records and major public company disclosures reviewed. The absence of a launched biosimilar does not mean that all patent barriers remain valid. It indicates that regulatory, technical, economic, or commercial entry conditions have not yet produced a marketed U.S. competitor.
How strong is the Mircera patent estate?
Mircera has moderate practical protection but limited growth protection.
Its strengths are:
- Complex PEGylated biologic structure
- Manufacturing and analytical barriers
- Established dialysis-center use
- Lack of an approved U.S. biosimilar
- Longstanding regulatory and clinical record
Its weaknesses are:
- Expired U.S. biologic exclusivity
- Mature ESA market
- Low-cost epoetin competition
- Reimbursement-driven purchasing pressure
- Potential design-around options for formulation and manufacturing
- Oral HIF-PH inhibitor competition
- Limited ability to raise price in concentrated dialysis markets
The estate is stronger as an operational and manufacturing barrier than as a simple monopoly based on one unexpired U.S. composition patent.
What generic or biosimilar launch scenarios exist?
Scenario 1: No U.S. biosimilar launch
Mircera retains a stable niche because development economics are unattractive, dialysis providers demand supply reliability, and competing ESAs already provide low-cost alternatives.
Scenario 2: Limited-label biosimilar launch
A biosimilar launches for selected CKD indications or administration settings. The entrant discounts heavily to win dialysis contracts but does not immediately achieve broad substitution.
Scenario 3: Broad biosimilar competition
A biosimilar receives a broad label and secures preferred status with major dialysis operators. Price erosion accelerates, and Mircera becomes a secondary product.
Scenario 4: Class substitution
Oral HIF-PH inhibitors gain share in non-dialysis CKD and selected dialysis patients. Mircera remains concentrated in patients for whom established injectable ESA treatment is preferred.
How does Mircera compare with competing anemia drugs?
| Attribute |
Mircera |
Darbepoetin alfa |
Epoetin alfa |
Daprodustat |
| Modality |
PEGylated erythropoietin biologic |
Modified erythropoietin biologic |
Recombinant erythropoietin biologic |
Oral small molecule |
| Administration |
Infrequent injection |
Weekly or less frequent injection |
Frequent injection |
Oral |
| Primary advantage |
Dosing convenience |
Established long-acting ESA |
Cost and familiarity |
No injection |
| Main weakness |
Mature product and price pressure |
ESA class risks |
Administration burden |
Newer safety and label constraints |
| Biosimilar risk |
Moderate potential, no identified U.S. launch |
High |
High and established |
Not applicable in the same biologic sense |
| Commercial stage |
Mature |
Mature |
Mature/genericized |
Earlier commercial lifecycle |
Key Takeaways
- Methoxy polyethylene glycol-epoetin beta is a long-acting PEGylated ESA marketed as Mircera.
- U.S. biologic exclusivity expired in 2019, but no FDA-approved Mircera biosimilar was identified in the reviewed Purple Book records.
- Mircera is not an Orange Book product, so conventional Paragraph IV analysis does not apply.
- The product’s protection depends on patent families covering composition, manufacturing, formulation, and methods of use.
- U.S. dialysis reimbursement, lower hemoglobin targets, ESA safety concerns, and low-cost epoetin competition have constrained demand.
- Daprodustat and other HIF-PH inhibitors create the main newer therapeutic threat.
- Roche does not consistently disclose Mircera revenue separately, preventing a reliable current standalone global sales series from public financial reports.
- The product is best viewed as a mature, recurring-revenue asset with moderate practical barriers and limited growth potential.
FAQs
Is methoxy polyethylene glycol-epoetin beta the same as epoetin alfa?
No. It is a chemically PEGylated erythropoietin derivative with a longer half-life and less frequent dosing than epoetin alfa.
Is Mircera interchangeable with an epoetin biosimilar?
No automatic interchangeability should be assumed. Mircera and epoetin biosimilars are different biologic products, and substitution depends on regulatory designation, prescriber authorization, payer policy, and local law.
Does Mircera have a generic version?
There is no conventional generic version because Mircera is a biologic. A competitor would generally need a biosimilar approval rather than an ANDA-based generic approval.
Can a company file a Paragraph IV challenge against Mircera?
Not in the conventional Orange Book sense. A competitor would use the BPCIA biologics framework and may litigate relevant patents under the applicable patent-dispute process.
Is Mircera still commercially relevant after U.S. exclusivity expired?
Yes. Its relevance comes from dosing convenience, established dialysis use, manufacturing complexity, and the absence of an identified approved U.S. biosimilar. Its long-term outlook remains mature rather than growth-oriented.
References
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2023). Mircera (methoxy polyethylene glycol-epoetin beta) prescribing information. FDA.
-
European Medicines Agency. (2007). Mircera: EPAR - product information. EMA.
-
U.S. Food and Drug Administration. (2021). Questions and answers on biosimilar development and the BPCI Act. FDA.
-
U.S. Food and Drug Administration. (2023). Jesduvroq (daprodustat) prescribing information. FDA.
-
Centers for Medicare & Medicaid Services. (2010). Medicare program; end-stage renal disease prospective payment system. Federal Register, 75(155).
-
Pfeffer, M. A., Burdmann, E. A., Chen, C. Y., et al. (2009). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine, 361(21), 2019-2032.
-
Roche Holding Ltd. (2024). Annual report 2023. Roche.
-
CSL Vifor. (2022). Annual report 2021. CSL Vifor.
